Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma

Daniel Trifiletti, M. Sean Peach, Zhiyuan Xu, Ronald Kersh, Timothy N. Showalter, Jason P. Sheehan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pilocytic astrocytomas are rare intracranial gliomas that are typically treated with surgical extirpation. Our aim was to report the radiologic and clinical outcomes of patients treated with stereotactic radiosurgery (SRS) for pilocytic astrocytoma in the primary and salvage setting. Patients with pilocytic astrocytoma treated at a single institution with SRS from 1990 to 2015 were reviewed. Patient, disease, and treatment characteristics were collected and overall survival, local control, and toxicity were evaluated. Twenty-eight consecutive patients (12 females and 16 males) with a median age of 17.4 years at SRS were identified. Overall, 46% of patients were treated with SRS as part of the initial treatment course after biopsy or subtotal resection, and the remainder as a salvage therapy. The most common location was the cerebellum (28%) followed by brainstem and basal ganglia (21 and 18%, respectively). Four patients received prior external beam radiation therapy (14%). Median tumor volume was 1.84 cc (0.19–15.94 cc), and 39% had a cystic component at SRS. Prescription dose ranged from 4 to 20 Gy (median 16 Gy) to a median isodose line of 50% (range 30–100%). With a median follow-up of 5.2 years (0.3–17.1 years), all patients remained alive at last follow-up. Two patients demonstrated evidence of local radiographic progression at last follow-up (7%). No toxicity could be directly attributed to SRS. In this SRS series, durable tumor control was achieved in 93% of patients with pilocytic astrocytoma, although continued follow up will be important giving the natural history of this disease. As demonstrated, SRS is an appropriate technique in the primary and recurrent treatment of pilocytic astrocytoma that offers favorable disease control and infrequent clinical toxicity.

Original languageEnglish (US)
Pages (from-to)297-302
Number of pages6
JournalJournal of neuro-oncology
Volume134
Issue number2
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Radiosurgery
Astrocytoma
Salvage Therapy
Basal Ganglia
Tumor Burden
Glioma
Cerebellum
Brain Stem
Prescriptions
Radiotherapy
Therapeutics
Biopsy
Survival

Keywords

  • Astrocytoma
  • Pilocytic
  • Radiosurgery
  • SRS

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma. / Trifiletti, Daniel; Peach, M. Sean; Xu, Zhiyuan; Kersh, Ronald; Showalter, Timothy N.; Sheehan, Jason P.

In: Journal of neuro-oncology, Vol. 134, No. 2, 01.09.2017, p. 297-302.

Research output: Contribution to journalArticle

Trifiletti, Daniel ; Peach, M. Sean ; Xu, Zhiyuan ; Kersh, Ronald ; Showalter, Timothy N. ; Sheehan, Jason P. / Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma. In: Journal of neuro-oncology. 2017 ; Vol. 134, No. 2. pp. 297-302.
@article{2fdd728284424e418b980dcb7ce62c0b,
title = "Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma",
abstract = "Pilocytic astrocytomas are rare intracranial gliomas that are typically treated with surgical extirpation. Our aim was to report the radiologic and clinical outcomes of patients treated with stereotactic radiosurgery (SRS) for pilocytic astrocytoma in the primary and salvage setting. Patients with pilocytic astrocytoma treated at a single institution with SRS from 1990 to 2015 were reviewed. Patient, disease, and treatment characteristics were collected and overall survival, local control, and toxicity were evaluated. Twenty-eight consecutive patients (12 females and 16 males) with a median age of 17.4 years at SRS were identified. Overall, 46{\%} of patients were treated with SRS as part of the initial treatment course after biopsy or subtotal resection, and the remainder as a salvage therapy. The most common location was the cerebellum (28{\%}) followed by brainstem and basal ganglia (21 and 18{\%}, respectively). Four patients received prior external beam radiation therapy (14{\%}). Median tumor volume was 1.84 cc (0.19–15.94 cc), and 39{\%} had a cystic component at SRS. Prescription dose ranged from 4 to 20 Gy (median 16 Gy) to a median isodose line of 50{\%} (range 30–100{\%}). With a median follow-up of 5.2 years (0.3–17.1 years), all patients remained alive at last follow-up. Two patients demonstrated evidence of local radiographic progression at last follow-up (7{\%}). No toxicity could be directly attributed to SRS. In this SRS series, durable tumor control was achieved in 93{\%} of patients with pilocytic astrocytoma, although continued follow up will be important giving the natural history of this disease. As demonstrated, SRS is an appropriate technique in the primary and recurrent treatment of pilocytic astrocytoma that offers favorable disease control and infrequent clinical toxicity.",
keywords = "Astrocytoma, Pilocytic, Radiosurgery, SRS",
author = "Daniel Trifiletti and Peach, {M. Sean} and Zhiyuan Xu and Ronald Kersh and Showalter, {Timothy N.} and Sheehan, {Jason P.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s11060-017-2521-x",
language = "English (US)",
volume = "134",
pages = "297--302",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma

AU - Trifiletti, Daniel

AU - Peach, M. Sean

AU - Xu, Zhiyuan

AU - Kersh, Ronald

AU - Showalter, Timothy N.

AU - Sheehan, Jason P.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Pilocytic astrocytomas are rare intracranial gliomas that are typically treated with surgical extirpation. Our aim was to report the radiologic and clinical outcomes of patients treated with stereotactic radiosurgery (SRS) for pilocytic astrocytoma in the primary and salvage setting. Patients with pilocytic astrocytoma treated at a single institution with SRS from 1990 to 2015 were reviewed. Patient, disease, and treatment characteristics were collected and overall survival, local control, and toxicity were evaluated. Twenty-eight consecutive patients (12 females and 16 males) with a median age of 17.4 years at SRS were identified. Overall, 46% of patients were treated with SRS as part of the initial treatment course after biopsy or subtotal resection, and the remainder as a salvage therapy. The most common location was the cerebellum (28%) followed by brainstem and basal ganglia (21 and 18%, respectively). Four patients received prior external beam radiation therapy (14%). Median tumor volume was 1.84 cc (0.19–15.94 cc), and 39% had a cystic component at SRS. Prescription dose ranged from 4 to 20 Gy (median 16 Gy) to a median isodose line of 50% (range 30–100%). With a median follow-up of 5.2 years (0.3–17.1 years), all patients remained alive at last follow-up. Two patients demonstrated evidence of local radiographic progression at last follow-up (7%). No toxicity could be directly attributed to SRS. In this SRS series, durable tumor control was achieved in 93% of patients with pilocytic astrocytoma, although continued follow up will be important giving the natural history of this disease. As demonstrated, SRS is an appropriate technique in the primary and recurrent treatment of pilocytic astrocytoma that offers favorable disease control and infrequent clinical toxicity.

AB - Pilocytic astrocytomas are rare intracranial gliomas that are typically treated with surgical extirpation. Our aim was to report the radiologic and clinical outcomes of patients treated with stereotactic radiosurgery (SRS) for pilocytic astrocytoma in the primary and salvage setting. Patients with pilocytic astrocytoma treated at a single institution with SRS from 1990 to 2015 were reviewed. Patient, disease, and treatment characteristics were collected and overall survival, local control, and toxicity were evaluated. Twenty-eight consecutive patients (12 females and 16 males) with a median age of 17.4 years at SRS were identified. Overall, 46% of patients were treated with SRS as part of the initial treatment course after biopsy or subtotal resection, and the remainder as a salvage therapy. The most common location was the cerebellum (28%) followed by brainstem and basal ganglia (21 and 18%, respectively). Four patients received prior external beam radiation therapy (14%). Median tumor volume was 1.84 cc (0.19–15.94 cc), and 39% had a cystic component at SRS. Prescription dose ranged from 4 to 20 Gy (median 16 Gy) to a median isodose line of 50% (range 30–100%). With a median follow-up of 5.2 years (0.3–17.1 years), all patients remained alive at last follow-up. Two patients demonstrated evidence of local radiographic progression at last follow-up (7%). No toxicity could be directly attributed to SRS. In this SRS series, durable tumor control was achieved in 93% of patients with pilocytic astrocytoma, although continued follow up will be important giving the natural history of this disease. As demonstrated, SRS is an appropriate technique in the primary and recurrent treatment of pilocytic astrocytoma that offers favorable disease control and infrequent clinical toxicity.

KW - Astrocytoma

KW - Pilocytic

KW - Radiosurgery

KW - SRS

UR - http://www.scopus.com/inward/record.url?scp=85020119131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020119131&partnerID=8YFLogxK

U2 - 10.1007/s11060-017-2521-x

DO - 10.1007/s11060-017-2521-x

M3 - Article

C2 - 28567590

AN - SCOPUS:85020119131

VL - 134

SP - 297

EP - 302

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -